Psoriasis trials in Germany
14 of 25 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 12 November 2026. Ask the study team whether a trial fits you.
- Phase 4Taking peopleAn open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
- Where
- Berlin
- People
- 339 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00 - Phase 1Taking peopleA Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
- Where
- Berlin, Hamburg, Ratingen, Wetzlar
- Age
- 18 years and over
- People
- 392 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT07290036 - Phase 3Taking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Hamburg, Sankt Augustin
- Age
- 3 years to 64 years
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - Phase 3Taking peopleLong-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
- Where
- Bad Bentheim, Berlin, Blankenfelde-Mahlow, Bramsche, Dresden, Erlangen, Frankfurt Am Main, Friedrichshafen, Halle, Hamburg, Heidelberg, Kiel, Langenau, Mainz, Memmingen, Merzig, Muenster, Quedlinburg, Tuebingen, Witten, Wuerzburg
- Age
- 40 years and over
- People
- 3,040 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07116967 · EU 2023-503766-24-00 - Phase 3Taking peopleA Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Berlin, Dresden, Erlangen, Mainz, Muenster
- Age
- 12 years to 17 years
- People
- 366 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06979453 · EU 2023-506296-97-00 - Phase 3Taking peopleA Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
- Where
- Berlin, Dresden, Hamburg, Mainz, Muenster
- Age
- 4 years to 18 years
- People
- 153 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT04772079 · EU 2022-502519-13-00 - Phase 2Taking peopleAn Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
- Where
- Bad Bentheim, Frankfurt Am Main, Heidelberg, Kiel
- Age
- 18 years and over
- People
- 240 worldwide
- Run by
- Oruka Therapeutics, Inc.
See details and how to joinNCT07449702 · EU 2026-526898-42-00 - Phase 3Taking peopleA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- Where
- Bad Bentheim, Bad Doberan, Berlin, Dresden, Hamburg, Leipzig, Munich, Ratingen
- Age
- 18 years and over
- People
- 1,088 worldwide
- Run by
- Takeda
See details and how to joinNCT06671483 · EU 2024-513111-27-00 - Phase 1Taking peopleA Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
- Where
- Freiburg im Breisgau, Herne
- Age
- 18 years and over
- People
- 20 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06888193 · EU 2024-518689-29-00 - Phase 3Taking peopleA Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
- Where
- Bad Bentheim, Bonn, Cologne, Frankfurt Am Main, Mainz, Muenster
- Age
- 4 years to 17 years
- People
- 110 worldwide
- Run by
- Takeda
See details and how to joinNCT07250802 · EU 2025-522567-15-00 - Phase 3Taking peopleContinuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- Where
- Bad Bentheim, Bad Doberan, Berlin, Dresden, Hamburg, Herne, Leipzig, Munich, Ratingen
- Age
- 18 years and over
- People
- 1,182 worldwide
- Run by
- Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00 - Phase 3Taking peopleA Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
- Where
- Berlin, Hamburg, Sankt Augustin
- Age
- 5 years to 17 years
- People
- 40 worldwide
- Run by
- AbbVie
See details and how to joinNCT06100744 · EU 2023-506026-36-00 - Phase 3Taking peopleA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
- Where
- Berlin, Bramsche, Dresden, Duesseldorf, Hamburg, Kiel, Langenau, Leipzig, Lübeck, Mannheim, Munich, Potsdam, Rostock
- Age
- 18 years and over
- People
- 320 worldwide
- Run by
- Janssen - Cilag International
See details and how to join2023-505121-14-00 · EU 2023-505121-14-00 - Phase 4Taking peopleSafety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis
- Where
- Bad Bentheim, Bonn, Frankfurt Am Main, Freiburg im Breisgau, Hamburg, Hanover, Marburg, Merzig, Muenster, Munich, Straubing, Wetzlar, Wuppertal
- Age
- 18 years and over
- People
- 336
- Run by
- Justus-Liebig-Universitaet Giessen
See details and how to join2024-512881-32-00 · EU 2024-512881-32-00